Loading...
BIOCON logo

Biocon LimitedNSEI:BIOCON Stock Report

Market Cap ₹531.6b
Share Price
₹398.35
n/a
1Y15.6%
7D3.2%
Portfolio Value
​
View

Biocon Limited

NSEI:BIOCON Stock Report

Market Cap: ₹531.6b

Biocon (BIOCON) Stock Overview

Manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. More details

BIOCON fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance2/6
Financial Health4/6
Dividends2/6

Rewards

Earnings are forecast to grow 55.02% per year

Risk Analysis

Profit margins (2.9%) are lower than last year (9.7%)


BIOCON Community Fair Values

Create Narrative

See what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.

BIOCON logo
Biocon

Growing Global Aging Demand Will Expand Affordable Biosimilars

Key Takeaways Strong biosimilar launches and strategic partnerships position Biocon for durable market share gains, resilient supply chains, and outperformance in operating margins and growth. Enhanced financial flexibility from deleveraging and capital raises enables faster reinvestment, capacity expansion, and potential for accelerated earnings growth beyond market expectations.
View narrative
₹465
FV
14.3% undervalued intrinsic discount
18.76%
Revenue growth p.a.
15
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BIOCON logo
Biocon

Rising Regulatory Scrutiny And Supply Risks Will Hamper Biosimilars

Key Takeaways Stricter regulations, protectionism, and approval delays threaten Biocon's biosimilar launches, international expansion, and sustained revenue growth. Heavy dependence on legacy products and slow adaptation to advanced therapies risk margin erosion, commoditization, and weaker long-term growth prospects.
View narrative
₹290
FV
37.4% overvalued intrinsic discount
13.78%
Revenue growth p.a.
12
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BIOCON logo
Biocon

Biosimilars Demand Will Unlock Global Market Opportunities

Key Takeaways Expanding biologics portfolio, global launches, and strategic partnerships position Biocon to capture growth from rising biosimilar demand and therapeutic market leadership. Enhanced operating leverage and manufacturing scale drive margin improvements and long-term earnings stability amid increasing healthcare spending and global market access.
View narrative
₹412.05
FV
3.3% undervalued intrinsic discount
15.30%
Revenue growth p.a.
101
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
View Stock Community

Biocon Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biocon
Historical stock prices
Current Share Price₹398.35
52 Week High₹424.95
52 Week Low₹291.00
Beta0.24
1 Month Change0.78%
3 Month Change11.91%
1 Year Change15.63%
3 Year Change51.00%
5 Year Change-13.16%
Change since IPO887.54%

Recent News & Updates

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

Recent updates

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Aug 04
Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

Jun 18
Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

Biocon (NSE:BIOCON) Has Affirmed Its Dividend Of ₹0.50

May 12
Biocon (NSE:BIOCON) Has Affirmed Its Dividend Of ₹0.50

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Apr 18
Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited's (NSE:BIOCON) Business Is Trailing The Market But Its Shares Aren't

Mar 10
Biocon Limited's (NSE:BIOCON) Business Is Trailing The Market But Its Shares Aren't

Does Biocon (NSE:BIOCON) Have A Healthy Balance Sheet?

Feb 20
Does Biocon (NSE:BIOCON) Have A Healthy Balance Sheet?

Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Feb 02
Biocon Limited Just Missed EPS By 81%: Here's What Analysts Think Will Happen Next

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Jan 19
Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

A Look At The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Jan 03
A Look At The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
User avatar

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

Shareholder Returns

BIOCONIN BiotechsIN Market
7D3.2%4.1%1.4%
1Y15.6%11.8%2.7%

Return vs Industry: BIOCON exceeded the Indian Biotechs industry which returned 11.8% over the past year.

Return vs Market: BIOCON exceeded the Indian Market which returned 2.7% over the past year.

Price Volatility

Is BIOCON's price volatile compared to industry and market?
BIOCON volatility
BIOCON Average Weekly Movement3.9%
Biotechs Industry Average Movement4.8%
Market Average Movement5.2%
10% most volatile stocks in IN Market8.5%
10% least volatile stocks in IN Market3.1%

Stable Share Price: BIOCON has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: BIOCON's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
197816,315Siddharth Mittalwww.biocon.com

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept.

Biocon Limited Fundamentals Summary

How do Biocon's earnings and revenue compare to its market cap?
BIOCON fundamental statistics
Market cap₹531.58b
Earnings (TTM)₹4.86b
Revenue (TTM)₹164.76b
109.5x
P/E Ratio
3.2x
P/S Ratio

Is BIOCON overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOCON income statement (TTM)
Revenue₹164.76b
Cost of Revenue₹66.04b
Gross Profit₹98.71b
Other Expenses₹93.86b
Earnings₹4.86b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 12, 2026

Earnings per share (EPS)3.64
Gross Margin59.91%
Net Profit Margin2.95%
Debt/Equity Ratio48.1%

How did BIOCON perform over the long term?

See historical performance and comparison

Dividends

0.1%
Current Dividend Yield
6%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 18:02
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biocon Limited is covered by 44 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Harith AhamedAvendus Spark
Vijayaraghavan SwaminathanAvendus Spark